UPDATED: Michel Vounatsos is on his way out as Biogen shutters Aduhelm effort and launches pipeline reorg - Endpoints News

Stymied by Medicare and forced to admit the end of its once sky-high hopes in the controversial Alzheimer's medicine Aduhelm, Biogen announced this morning that CEO Michel Vounatsos is being replaced as the big biotech restructures the pipeline, hunts deals a…

If the pleasantries exchanged today between the Biogen board and CEO Michel Vounatsos looked a bit intricately scripted to you, even by corporate PR standards, their 10Q filed with the SEC offers a p… [+660 chars]

full article...